Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

NTRA

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

NTRA

AI Research Report

Powered by Claude

Ready to analyze NTRA

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Natera Inc

Natera Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 2015-07-02
📅 Earnings in 22d (May 7)
NASDAQ NMS - GLOBAL MARKETMarket closed
Natera Inc
Biotechnology
$214.64
$12.74 (+6.31%)
Open
$207.52
Prev close
$201.90
Day range
$206.36 – $215.00
52W range
$131.81 – $256.36
Mkt cap
$30.42B
P/E
—
EPS
$-1.53
Beta
1.67

Analyst Consensus

Buy
Based on 28 analysts
Period: 2026-04-01
25 Buy (89%)3 Hold (11%)0 Sell (0%)
Rating Distribution
Strong Buy
10
Buy
15
Hold
3
Sell
0
Strong Sell
0
Trend
2026-04
25/3/0
2026-03
25/3/0
2026-02
24/3/0
2026-01
24/3/0

Fundamentals

Valuation
Market Cap
$30.42B
P/E (TTM)
—S&P avg ~22
P/S (TTM)
13.17S&P avg ~2.8
P/B
18.50S&P avg ~4.5
P/FCF
399.03S&P avg ~26
EPS (TTM)
$-1.53
Book/sh
$12.26
Cash/sh
$7.70
Profitability
Gross Margin
64.75%avg ~45%
Operating Margin
-13.44%avg ~15%
Net Margin
-9.03%avg ~12%
ROE
-15.28%avg ~18%
ROA
-10.80%avg ~7%
ROI
-14.43%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
35.90%
Rev Growth 5Y
42.61%
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
3.11
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.67
52W High
$256.36
52W Low
$131.81
Avg Vol (10D)
1.34M
Avg Vol (3M)
1.20M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (28)
Price Performance
5D-3.52%
MTD+0.95%
3M-15.72%
6M+18.50%
YTD-11.87%
1Y+40.91%

Factor Grades

View details →
C
Overall score: 50/100
D-
Valuation
A+
Growth
D
Profitability
C
Momentum
C
Financial Health
  • Benzinga·10h ago

    Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst

    William Blair starts Natera coverage, citing MRD growth potential, strong moat, and diversified pipeline supporting long-term outlook.

  • Benzinga·14h ago

    William Blair Initiates Coverage On Natera with Outperform Rating

    William Blair analyst Andrew Brackmann initiates coverage on Natera (NASDAQ:NTRA) with a Outperform rating.

  • Benzinga·1d ago

    Allogene Therapeutics Stock Hits 52-Week High - Here's Why

    Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.

  • Benzinga·1d ago

    Natera shares are trading higher amid sympathy with Allogene Therapeutics, which used the company's technology in its Phase 2 lymphoma trial.

  • Finnhub·1d ago

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. , a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics’ interim futility analysis from its registrational ALPHA3 trial for cemacabtagene...

  • Benzinga·5d ago

    Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle

    Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.

  • Benzinga·5d ago

    Natera Says Delaware Court Awards 30% Ongoing Royalty On MRD-Related Products In ArcherDx And Invitae Litigation, Upholds Prior Jury Royalty

  • View all news →

Recent insider activity

View all →
  • 4Insider transaction
    7d ago
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    14d ago
  • 4Insider transaction
    26d ago